Unum Group (NYSE:UNM) will announce its fourth quarter results on Wednesday, Feb. 2, at approximately 4 p.m. Eastern. The earnings news release and the financial supplement will be available in the “Investors” section of the company’s website at www.investors.unum.com.
Members of Unum Group senior management will host a conference call on Thursday, Feb. 3, at 9 a.m. Eastern to discuss the results of operations for the fourth quarter. Topics may include forward-looking information, such as guidance on future results or trends in operations, as well as other material information.
Unum Group, together with its subsidiaries, provides group and individual disability insurance products primarily in the United States and the United Kingdom.
Enzo Biochem, Inc. (NYSE:ENZ) is a leading life sciences and biotechnology company focused on harnessing genetic processes to develop research tools, diagnostics and therapeutics and provides reference laboratory services to the medical community.
Founded in 1976, we have concentrated on the development of enabling technologies in the areas of gene regulation and gene modification. Many of our technologies are applicable to the biomedical and pharmaceutical research markets, and we are further using these technologies as a platform for our entry into the clinical diagnostics market.
The business activities of Enzo Biochem are performed by the company’s three wholly owned subsidiaries . . . Enzo Life Sciences, Enzo Therapeutics and Enzo Clinical Labs. Enzo’s vision of the importance of recombinant DNA technology as an informational source more than two decades ago has now become a major direction in modern medicine.
Enzo Therapeutics is a growing and expanding biotechnology company, currently conducting research that is on the forefront of several fields of medical science. Enzo Therapeutics is developing new products and therapies based on novel technology platforms for the treatment of a variety of diseases and disorders.
Enzo Life Sciences is a leading manufacturer of high quality reagents, kits and products supplied to scientific researchers in academia, clinical research and drug discovery. With direct sales operations in US, Switzerland, Germany, UK, France and Benelux, Enzo Life Sciences also supports its 8000 products through a global network of dedicated distributors.
ENZO Opperational Highlights:
- Enzo Life Sciences, benefiting from increased emphasis on higher margin products, realized a greater than 100% gain in operating income.
- Enzo Clinical Labs increased revenues 6%, while reducing the operating loss 62%.
- Company-wide, gross margin increased $2.0 million or 17%.
- Operating expenses decreased 7%, or to 57% of revenues, from 63%.
- EBITDA, a non-GAAP measure, was $23,000, an improvement of $2.9 million from the prior quarter.
- Net loss for the quarter was reduced 70%.
Enzo Clinical Labs is a full service clinical reference laboratory. We are one of the leading regional labs in the country, as we combine the extensive testing capabilities of a large laboratory with the convenience and personalized service of a local one. Enzo was one of the area’s first laboratories to be awarded the prestigious College of American Pathologist (CAP) accreditation.
This award indicates that Enzo has passed an extremely rigorous series of inspections far more sophisticated than those mandated by licensing authorities.
Tortoise Power and Energy Infra (NYSE:TPZ) announced that as of December 31, 2010, the company’s unaudited total assets were approximately $205.5 million and its unaudited net asset value was $171.7 million, or $24.74 per share. As of December 31, 2010, the company was in compliance with its asset coverage ratio under the Investment Company Act of 1940 (the 1940 Act) and basic maintenance covenants.
The company’s asset coverage ratio under the 1940 Act with respect to senior securities representing indebtedness was 635 percent. For more information on calculation of coverage ratios, please refer to our most recent applicable prospectus.
American Video Teleconferencing Corp. (PINK: AVOT) is pleased to announce that it has hired a French speaking geologist to search the archives of the Quebec Department of Mines for Rare Earths showings not on a current computer file. The company believes the rare earths industry is where it wants to maintain a very strong focus and is looking to expand its holdings.
As neither the Federal nor Quebec Governments have carried out any air borne surveys in this area, the company will seek a contractor to do an air borne Mag-EM radiometric survey. This survey will cover its present holdings and the immediate surrounding area looking for future acquisitions. We are pleased to be working in the Province of Quebec as it is rated the number one jurisdiction in the world to carry out mineral exploration. The Quebec Government gives a rebate up to 45% for property expenditures.
The 17 elements which are classified as “rare earth” are becoming an ever more crucial aspect of our everyday lives. Rare earth metals are the life blood of modern computers, batteries and alternative energies. For instance, there are almost ten lbs of the rare earth element, lanthanum, in each and every Toyota Prius motor. Additionally, rare earth elements are crucial to military technologies. Contrary to the name, rare earth metals are not particularly uncommon and may be found in most any region throughout the world. In recent weeks the government made significant strides to increase production of these types of metals, as they will play a significant part in President Obama’s upgrades to US energy.
China is the world’s biggest producer of rare earth elements, most are used in today’s technologies, which include new energy sources and hybrid cars. It announced in July that it will cut exports for minerals used to make hybrid cars and televisions by 72 percent.
Presently American Video is in the final stage of negotiations with Kondor Gold Pyt. in Australia.
American Video will aggressively continue to search world-wide for opportunities in Precious, Base and Rare Earths metal projects.
PerkinElmer Inc. (NYSE:PKI) a global leader focused on improving the health and safety of people and the environment, announced that the Company will present at the JP Morgan Healthcare Conference on Tuesday, January 11, 2011, at 10:00 am Pacific Time at the Westin St Francis Hotel in San Francisco.
Robert F. Friel, PerkinElmer’s chairman and chief executive officer, will provide an overview of the Company and its strategic objectives. A live audio webcast of this presentation will also be available on the Investor section of the Company's Web site at www.perkinelmer.com.
PerkinElmer, Inc. provides technology, services, and solutions to the diagnostics, research, environmental, safety and security, industrial and laboratory services markets. PerkinElmer has the portfolios of functional cellular science research technologies.
Sign-Up For Free Stock Alerts At http://crwepicks.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.The CRWEPicks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer ( http://crwepicks.com/disclaimer ) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEPicks.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. ( read more at http://crwepicks.com/disclaimer ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.
Crown Equity Holdings Inc. (OTCPK:CRWE) has received from the company 2,000,000 shares of (144) restricted common stock of American Video Teleconferencing Corp. (OTCPK:AVOT) for 12 months IR Services and 1,000,000 shares of (144) restricted common stock for its IT services.